Dave Denton, chief financial officer of Pfizer Inc., center left, and Albert Bourla, chief executive officer of Pfizer Inc., center, ring the closing bell on the floor of the New York Stock Exchange (NYSE) in New York, US, on Wednesday, March 4, 2026.
Michael Nagle | Bloomberg | Getty Images
Pfizer said on Thursday that finance chief Dave Denton will step down and leave the U.S. drugmaker on August 15 to take a role in the consumer goods industry.
The company named Cecile Guegan, senior vice president of finance for its global biopharmaceutical business, as interim CFO, effective August 16.
Denton joined Pfizer as its finance head in 2022, having previously held positions at healthcare conglomerate CVS and retail chain Lowe’s Companies.
Pfizer’s top boss, Albert Bourla, said in a statement that Denton had helped guide the company through major transactions, including the buyouts of cancer therapy specialist Seagen, migraine drugmaker Biohaven and obesity drug developer Metsera.
Shares of the company were down 1.6% in premarket trading.
Pfizer said it will conduct an internal and external search for a permanent successor. Denton and Guegan will work together on the transition, the company said.
Source link
#Pfizer #CFO #Dave #Denton #step #leave #company #August
